

ARGENICA APPOINTS HEAD OF CLINICAL DEVELOPMENT TO LEAD ALL CLINICAL DEVELOPMENT PROGRAMS

Perth, Australia; 13 JANUARY 2022 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce the appointment of experienced healthcare and clinical trials professional Dr Meghan Thomas, as Head of Clinical Development.

Dr Thomas will join Argenica in its Perth office in early April and provide leadership, project management and program oversight for the timely preparation and execution of the Company’s upcoming Phase 1 clinical trial program. Dr Thomas will also manage the Company’s future clinical trials as Argenica moves into later stage clinical development.

Dr Thomas has significant experience in managing clinical trials, and joins Argenica from Zelira Therapeutics Ltd (ASX:ZLD) where she was Vice President of Clinical Programs and Operations. In this role, Dr Thomas was responsible for overseeing the clinical trial program, Australian commercial manufacturing operations, and the regulatory affairs requirements to progress Zelira’s lead therapies through to commercialisation.

Prior to joining Zelira, Dr Thomas worked in Clinical Planning and with Human Research Ethics Committees across Government Health Departments in Perth, Western Australia. She holds a Doctor of Philosophy in Neuroscience from the University of Western Australia, a Bachelor of Science (Honours) from the University of Western Australia and Edith Cowan University, and is trained in Good Clinical Practice and Regulatory Requirements for Clinical Trials.

Argenica’s CEO, Dr Liz Dallimore said: “We are delighted to welcome Meghan to the Argenica team. She brings a wealth of experience managing Australian and global clinical trials and manufacturing, understanding the complexities of regulation, ethics, as well as the commercial pressures a small biotechnology company faces. She is a huge asset for us moving forward as we move into our Phase 1 clinical trial for ARG-007 and expand out our clinical program in the future”.

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.